Following promising clinical data , retatrutide, a new peptide option for addressing non-insulin dependent hyperglycemia , has received conditional approval from the Medicines and Healthcare Agency ( MHRA body). Initial availability is currently expected via specialist weight-related centres and particular healthcare trusts in late year , with wide